Dimerix (ASX:DXB) opened a pediatric site in Mexico for its ongoing phase three trial investigating the use of DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Thursday filing with the Australian bourse.
The trial site is now ready to recruit patients ages 12 to 17 who will be given the same dose as adults, the biopharmaceutical firm said in the filing. An additional 14 pediatric sites will be opened in the US, the UK, and Argentina.
An interim analysis for the trial is set for release in the middle of 2025, per the filing.
Dimerix's shares climbed almost 4% in recent Thursday trade.
Price (AUD): $0.41, Change: $+0.015, Percent Change: +3.85%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。